Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 ...
Sep 30, 2012
0
0